$300 Million is the total value of Decheng Capital Management III (Cayman), LLC's 26 reported holdings in Q3 2023. The portfolio turnover from Q2 2023 to Q3 2023 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| NBSE | Exit | NeuBase Therapeutics, Inc. | $0 | – | -50,000 | -100.0% | -0.03% | – |
| Exit | GeneDx Holdings Corp. | $0 | – | -103,604 | -100.0% | -0.19% | – | |
| Exit | Apexigen, Inc. | $0 | – | -1,894,551 | -100.0% | -0.26% | – | |
| Exit | AtriCure Inc. | $0 | – | -46,259 | -100.0% | -0.72% | – | |
| SGEN | Exit | Seagen Inc. | $0 | – | -23,014 | -100.0% | -1.39% | – |
| Exit | BeyondSpring Inc. | $0 | – | -4,958,143 | -100.0% | -1.84% | – | |
| Exit | ROIVANT SCIENCES LTD | $0 | – | -1,459,700 | -100.0% | -4.62% | – | |
| ALPPRNCL | Exit | Alpine Immune Sciences, Inc. | $0 | – | -6,708,288 | -100.0% | -21.63% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2023-12-12
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Illumnia, Inc. | 7 | Q3 2023 | 16.5% |
| Cue Health Inc. | 7 | Q3 2023 | 17.8% |
| Arcus BioSciences, Inc. | 7 | Q3 2023 | 8.4% |
| 10x Genomics, Inc. | 7 | Q3 2023 | 8.1% |
| Pacific Biosciences of California, Inc. | 7 | Q3 2023 | 6.8% |
| Equillium Inc. | 7 | Q3 2023 | 4.3% |
| Aadi Bioscience, Inc. | 7 | Q3 2023 | 2.7% |
| Adicet Bio, Inc. | 7 | Q3 2023 | 3.6% |
| Aura Biosciences, Inc. | 7 | Q3 2023 | 6.1% |
| Terns Pharmaceuticals, Inc. | 7 | Q3 2023 | 3.4% |
View Decheng Capital Management III (Cayman), LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-01-22 |
| 13F-HR/A | 2023-12-12 |
| 13F-HR/A | 2023-11-29 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-07-28 |
| 13F-HR | 2023-05-10 |
| 13F-HR | 2023-02-09 |
| 13F-HR | 2022-11-08 |
| 4 | 2022-09-27 |
| 13F-HR | 2022-08-01 |
View Decheng Capital Management III (Cayman), LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.